Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 23:14:35 05/10/2021 HKT			5-day change	1st Jan Change
4.510 ^USD	-5.65%		-2.45%	-

07-28	Cosmos Health Advances its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C And B2B Channels	CI
07-14	Cosmos Health Inc. And Libytec Pharmaceutical S.A. Enters Distribution And Promotion Agreement For DIABIT-IS X In Greece	CI

Market Cap	11.94M 10.35M 9.69M 8.84M 16.64M 1.14B 16.92M 114M 44.52M 570M 44.85M 43.87M 1.9B	P/E 2026 *	22x	P/E 2027 *	3.14x
Enterprise Value	11.94M 10.35M 9.69M 8.84M 16.64M 1.14B 16.92M 114M 44.52M 570M 44.85M 43.87M 1.9B	EV / Sales 2026 *	0.14x	EV / Sales 2027 *	0.11x
Free-Float	63.51%	Yield 2026 *	-	Yield 2027 *	-

07-28	Cosmos Health Advances its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C And B2B Channels	CI
07-14	Cosmos Health Inc. And Libytec Pharmaceutical S.A. Enters Distribution And Promotion Agreement For DIABIT-IS X In Greece	CI
07-14	Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug	MT
07-11	Cosmos Health Inc. Launches Subscription-Based Purchasing Model for Its Proprietary Consumer Health Brands	CI
07-10	Cosmos Health Launches Subscription-Based Purchasing Model	MT
07-08	Cosmos Health Inc. Provides Preliminary Revenue Guidance for the Second Quarter and First Half 2026	CI
07-03	Cosmos Health Expands Share Buyback to 3.4 Million Shares	MT
06-30	Cosmos Health Inc. announces an Equity Buyback for $5 million worth of its shares.	CI
06-30	Cosmos Health Inc. authorizes a Buyback Plan.	CI
06-27	Cosmos Health Signs Qatar Distribution Deal With IMC	MT
06-27	Cosmos Health Inc. Signs Distribution Agreement with International Medical Company, and Secures Initial Purchase Order of 31,000 Sky Premium Life Units	CI
06-24	Cosmos Health to Deploy AI-Powered Call Center at Pharma Distribution Unit	MT
06-19	Cosmos Health Inc. Expands AI Automation and Facility Capacity	CI

07-28	Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels	GL
07-21	Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units	GL
07-18	Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases	GL
07-17	Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases	GL
07-16	Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases	GL

Cosmos Holdings Inc. Stock OTC Markets

Stocks

COSM

US2214131078

Pharmaceuticals

Valuation: Cosmos Holdings Inc.

Latest news : Cosmos Holdings Inc.

Press Releases: Cosmos Holdings Inc.

News in other languages: Cosmos Holdings Inc.

Quotes and Performance

Managers and Directors: Cosmos Holdings Inc.

Pharmaceuticals Wholesale

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

29/11/24	Dalla farmaceutica al fitness: la corsa all'oro del bitcoin - Crypt On It
28/11/24	De la farmacia al gimnasio: la fiebre del bitcoin - Crypto Recap
05/12/22	Pelè non è in cure palliative - figlia
01/12/22	BASF : lance un agent nacrant naturel à base de cire

Manager	Title	Age	Since
Grigorios Siokas CEO	Chief Executive Officer	60	26/02/2016
Georgios Terzis DFI	Director of Finance/CFO	43	11/11/2020
Nikolaos Bardakis COO	Chief Operating Officer	56	01/02/2023

Director	Title	Age	Since
Demetrios Demetriades BRD	Director/Board Member	58	13/01/2014
Grigorios Siokas CHM	Chairman	60	26/02/2016
John Hoidas BRD	Director/Board Member	59	18/11/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
COSMOS HOLDINGS INC.	-5.65%	-2.45%	-	-	11.94M
MCKESSON CORPORATION	+2.49%	+8.59%	+34.04%	+104.92%	105B
CARDINAL HEALTH, INC.	+1.30%	+2.87%	+52.39%	+160.08%	55.88B
SIGMA HEALTHCARE LIMITED	-0.34%	-0.67%	+3.86%	+267.70%	24.12B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	-0.18%	+0.36%	-12.43%	-13.43%	8.28B
HUADONG MEDICINE CO., LTD	+0.61%	+4.63%	-29.94%	-24.40%	7.75B
SINOPHARM GROUP CO. LTD.	-0.48%	-2.95%	-12.07%	-21.55%	6.69B
H. LUNDBECK A/S	-0.80%	-0.82%	+16.80%	+16.07%	6.16B
GALENICA AG	-0.49%	-3.78%	-4.68%	+19.96%	5.01B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+0.40%	+0.20%	-5.59%	-4.42%	3.75B
Average	-0.31%	+2.09%	+4.71%	+56.10%	24.75B
Weighted average by Cap.	+1.44%	+5.01%	+28.02%	+117.47%

	2026 *	2027 *
Net sales	84.3M 73.05M 68.39M 62.4M 117M 8.04B 119M 802M 314M 4.02B 317M 310M 13.43B	111M 96.02M 89.89M 82.02M 154M 10.57B 157M 1.05B 413M 5.29B 416M 407M 17.65B
Net income	-	-
Net Debt	-	-